REGENERON PHARMACEUTICALS, INC. Insider Trading Activity
Every SEC Form 4 insider transaction reported for REGENERON PHARMACEUTICALS, INC. (REGN), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are REGN insiders buying or selling?
In the last 12 months, REGENERON PHARMACEUTICALS, INC. insiders reported 0 open-market purchases ($0) and 16 sales ($16.1M) — net selling of $16.1M. Since February 2018, Trabud has recorded 354 Form 4 filings for REGN: 0 buys ($0) and 354 sells ($13.6B).
Source: SEC EDGAR Form 4
What stands out
- No REGENERON PHARMACEUTICALS, INC. insider made an open-market purchase in the last 12 months; the 16 reported open-market sales totaled $16.1M.
Key Statistics (February 2018 – Oct 15, 2026)
Total Form 4 filings
354
SEC EDGAR
Insider filers
22
Insider buys (0)
$0
Insider sells (354)
$13.6B
Insider sentiment
Net sellingNet insider flow of $13.6B in net selling since February 2018, and $16.1M in net selling over the last 12 months.
Recent REGN insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 15, 2026 | Andrew J Murphy | Co-Chief Scientific Officer | Sale | 4.1K | $772.70 | $3.2M | SEC ↗ |
| Sep 3, 2026 | Marion Mccourt | EVP Commercial | Sale | 2.3K | $853.56 | $2.0M | SEC ↗ |
| Sep 3, 2026 | Kathryn Guarini | Director | Sale | 400 | $850.00 | $340.0K | SEC ↗ |
| Aug 12, 2026 | Kathryn Guarini | Director | Sale | 400 | $800.00 | $320.0K | SEC ↗ |
| Aug 12, 2026 | Huda Y Zoghbi | Director | Sale | 800 | $800.00 | $640.0K | SEC ↗ |
| Jul 7, 2026 | Arthur F Ryan | Director | Sale | 200 | $650.15 | $130.0K | SEC ↗ |
| May 4, 2026 | Arthur F Ryan | Director | Sale | 100 | $705.24 | $70.5K | SEC ↗ |
| Apr 3, 2026 | Arthur F Ryan | Director | Sale | 100 | $777.27 | $77.7K | SEC ↗ |
| Mar 3, 2026 | Arthur F Ryan | Director | Sale | 100 | $785.50 | $78.5K | SEC ↗ |
| Feb 23, 2026 | Huda Y Zoghbi | Director | Sale | 1.6K | $781.33 | $1.3M | SEC ↗ |
| Feb 11, 2026 | Jason Pitofsky | SVP Controller | Sale | 2.0K | $778.52 | $1.6M | SEC ↗ |
| Feb 11, 2026 | Arthur F Ryan | Director | Sale | 100 | $778.53 | $77.9K | SEC ↗ |
| Jan 8, 2026 | Bonnie L Bassler | Director | Sale | 1.5K | $800.00 | $1.2M | SEC ↗ |
| Nov 24, 2025 | Bonnie L Bassler | Director | Sale | 760 | $750.00 | $570.0K | SEC ↗ |
| Nov 10, 2025 | Jason Pitofsky | VP Controller | Sale | 431 | $651.43 | $280.8K | SEC ↗ |
| Oct 31, 2025 | Christine A Poon | Director | Sale | 6.5K | $654.27 | $4.3M | SEC ↗ |
| Nov 5, 2024 | Marion Mccourt | EVP Commercial | Sale | 1.0K | $844.61 | $844.6K | SEC ↗ |
| Oct 3, 2024 | Arthur F Ryan | Director | Sale | 100 | $1048.78 | $104.9K | SEC ↗ |
| Oct 3, 2024 | Marion Mccourt | EVP Commercial | Sale | 1.0K | $1054.06 | $1.1M | SEC ↗ |
| Sep 5, 2024 | Marion Mccourt | EVP Commercial | Sale | 1.0K | $1178.73 | $1.2M | SEC ↗ |
| Sep 5, 2024 | Arthur F Ryan | Director | Sale | 100 | $1178.69 | $117.9K | SEC ↗ |
| Aug 29, 2024 | Christopher R. Fenimore | SVP Finance & CFO | Sale | 5.7K | $1205.33 | $6.8M | SEC ↗ |
| Aug 19, 2024 | Bonnie L Bassler | Director | Sale | 756 | $1170.00 | $884.5K | SEC ↗ |
| Aug 19, 2024 | Christine A Poon | Director | Sale | 10.8K | $1158.17 | $12.6M | SEC ↗ |
| Aug 15, 2024 | Andrew J Murphy | EVP Research | Sale | 6.4K | $1153.15 | $7.3M | SEC ↗ |
Showing the 25 most recent of 354 Form 4 filings for REGENERON PHARMACEUTICALS, INC..
Most active REGN insiders
- Arthur F Ryan53 filings
- Marion Mccourt46 filings
- Robert E Landry31 filings
- Joseph L Goldstein25 filings
- Bonnie L Bassler23 filings
Ask anything about REGN insider activity
Use Trabud's AI agent to query REGENERON PHARMACEUTICALS, INC.'s Form 4 history in plain English — "Show me REGN CEO purchases this year" or compare it against any other ticker.
Open the AI agentREGN insider trading FAQ
Are REGENERON PHARMACEUTICALS, INC. insiders buying or selling?
In the last 12 months, REGENERON PHARMACEUTICALS, INC. insiders reported 0 open-market purchases ($0) and 16 sales ($16.1M) — net selling of $16.1M. Since February 2018, Trabud has recorded 354 Form 4 filings for REGN: 0 buys ($0) and 354 sells ($13.6B). Over the full record that is net selling of $13.6B.
How many insiders trade REGN stock?
22 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for REGENERON PHARMACEUTICALS, INC.. The most recent filing was accepted on Oct 15, 2026.
Where does Trabud get REGN insider trading data?
All REGN insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.